120
Participants
Start Date
May 28, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
April 30, 2026
Artemether-lumefantrine
Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.
Dihydroartemisinin-Piperaquine
Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
RECRUITING
Dr. Ambrosoli Memorial Hospital, Kalongo
RECRUITING
Patongo Health Facility IV, Patongo
London School of Hygiene and Tropical Medicine
OTHER
Radboud University Medical Center
OTHER
Infectious Diseases Research Collaboration, Uganda
OTHER